WO2012013331A3 - Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases - Google Patents

Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases Download PDF

Info

Publication number
WO2012013331A3
WO2012013331A3 PCT/EP2011/003737 EP2011003737W WO2012013331A3 WO 2012013331 A3 WO2012013331 A3 WO 2012013331A3 EP 2011003737 W EP2011003737 W EP 2011003737W WO 2012013331 A3 WO2012013331 A3 WO 2012013331A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
fatty acids
polyunsaturated fatty
active pharmaceutical
capsules
Prior art date
Application number
PCT/EP2011/003737
Other languages
French (fr)
Other versions
WO2012013331A2 (en
Inventor
Antonio PARENTE DUEÑA
Original Assignee
Gp-Pharm, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gp-Pharm, S.A. filed Critical Gp-Pharm, S.A.
Publication of WO2012013331A2 publication Critical patent/WO2012013331A2/en
Publication of WO2012013331A3 publication Critical patent/WO2012013331A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Abstract

Pharmaceutical composition in capsule form which contains polyunsaturated fatty acids (PUFA) and active pharmaceutical ingredients for the treatment and/or prevention of prostate diseases and/or hyperandrogenic disorders.
PCT/EP2011/003737 2010-07-26 2011-07-26 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases WO2012013331A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201031146 2010-07-26
ES201031146A ES2385240B1 (en) 2010-07-26 2010-07-26 CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.

Publications (2)

Publication Number Publication Date
WO2012013331A2 WO2012013331A2 (en) 2012-02-02
WO2012013331A3 true WO2012013331A3 (en) 2012-06-28

Family

ID=44630202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/003737 WO2012013331A2 (en) 2010-07-26 2011-07-26 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases

Country Status (2)

Country Link
ES (1) ES2385240B1 (en)
WO (1) WO2012013331A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20090061B1 (en) 2008-02-11 2021-08-17 Ferring Int Center Sa METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
US20130280323A1 (en) * 2012-04-13 2013-10-24 Banner Pharmacaps, Inc. Soft Elastic Capsules Containing Tablets and Liquid or Semisolid Fills and Methods for Their Manufacture
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
CN104334182B (en) * 2012-06-01 2017-09-08 辉凌公司 Manufacture Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Lys(iPr)-Pro-D-Ala-NH2
RU2016114805A (en) * 2013-10-08 2017-11-15 Ферринг Бв Microparticles containing GnRH manufactured by PGSS (particle formation in gas-saturated solutions)
CN103788366B (en) * 2014-01-22 2015-10-28 沈阳药科大学 Mono methoxy polyethylene glycol-two sulphur-two VE-succinate and Synthesis and applications thereof
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
DK3110408T3 (en) 2014-02-28 2019-04-29 Banner Life Sciences Llc ENTERY SOFT CAPS OF CONTROLLED RELEASE FUMAR TESTERS
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9895333B2 (en) * 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
AU2017272888B2 (en) * 2016-06-03 2020-04-30 Avexxin As Combination therapy comprising a polyunsaturated ketone and a secosteroid
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CN113750032A (en) * 2020-06-01 2021-12-07 成都海博为药业有限公司 Oral abiraterone medicinal composition and preparation method and application thereof
CN111905106A (en) * 2020-09-14 2020-11-10 陕西科技大学 Slow-release sodium alginate/chitosan/zein composite material and preparation method thereof
EP4282417A1 (en) * 2022-05-26 2023-11-29 Recordati Industria Chimica E Farmaceutica SPA Association of tadalafil and vitamin d3 for use in the oral treatment of benign prostatic hypertrophy and production methods thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008537A1 (en) * 1989-02-06 1990-08-09 Abbott Laboratories Pharmaceutical compositions for oral administration
JPH0977663A (en) * 1995-07-07 1997-03-25 Nippon Kayaku Co Ltd Flutamide composition
WO1998002133A1 (en) * 1995-04-04 1998-01-22 Tien Henry C Compositions and methods for the treatment of male-pattern baldness
WO2001028566A1 (en) * 1999-10-19 2001-04-26 Instituto Helmaprost, S.L. Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1352648A1 (en) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils
WO2004084870A1 (en) * 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
CN1765363A (en) * 2005-10-21 2006-05-03 宛六一 Naftopidil soft capsule and its preparation method
WO2011060945A2 (en) * 2009-11-20 2011-05-26 Gp Pharm, S.A. Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
WO2011060944A2 (en) * 2009-11-20 2011-05-26 Gp Pharm, S.A. Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
WO2011060943A1 (en) * 2009-11-20 2011-05-26 Gp Pharm, S.A. Pharmaceutical formulations containing beta- blocking active ingredient capsules and polyunsaturated fatty acid esters

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (en) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
GB8506027D0 (en) 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US5952003A (en) 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
GB9717428D0 (en) 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
AU2870899A (en) 1998-02-26 1999-09-15 Abbott Laboratories Oral formulation for hydrophilic drugs
CA2339991C (en) 1998-08-13 2007-01-02 Cima Labs Inc. Microemulsions as solid dosage forms for oral administration
US6656969B2 (en) 2001-09-20 2003-12-02 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
US20060204588A1 (en) 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
EP2050436A1 (en) 2007-12-21 2009-04-22 Siegfried Generics International AG Pharmaceutical composition containing dutasteride

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008537A1 (en) * 1989-02-06 1990-08-09 Abbott Laboratories Pharmaceutical compositions for oral administration
WO1998002133A1 (en) * 1995-04-04 1998-01-22 Tien Henry C Compositions and methods for the treatment of male-pattern baldness
JPH0977663A (en) * 1995-07-07 1997-03-25 Nippon Kayaku Co Ltd Flutamide composition
WO2001028566A1 (en) * 1999-10-19 2001-04-26 Instituto Helmaprost, S.L. Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1352648A1 (en) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils
WO2004084870A1 (en) * 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
CN1765363A (en) * 2005-10-21 2006-05-03 宛六一 Naftopidil soft capsule and its preparation method
WO2011060945A2 (en) * 2009-11-20 2011-05-26 Gp Pharm, S.A. Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
WO2011060944A2 (en) * 2009-11-20 2011-05-26 Gp Pharm, S.A. Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
WO2011060943A1 (en) * 2009-11-20 2011-05-26 Gp Pharm, S.A. Pharmaceutical formulations containing beta- blocking active ingredient capsules and polyunsaturated fatty acid esters

Also Published As

Publication number Publication date
ES2385240A1 (en) 2012-07-20
WO2012013331A2 (en) 2012-02-02
ES2385240B1 (en) 2013-09-23

Similar Documents

Publication Publication Date Title
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
WO2011060945A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
PH12016500216A1 (en) Stable pharmaceutical composition and methods of using same
WO2011060944A3 (en) Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
GB2459809A (en) Fatty acid formulations and methods of use thereof
MX2016004487A (en) Enteric soft capsules comprising polyunsaturated fatty acids.
MX2012003555A (en) Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same.
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2014005013A3 (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
WO2011133841A3 (en) Intravenous omega-3 fatty acid compositions & method of use
EP2506848A4 (en) Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
MX2015016497A (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
UA96794C2 (en) Glucocorticoides, method of use thereof, treatment method and pharmaceutical formulation based thereon
MX353580B (en) Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections.
WO2013068960A3 (en) Monounsaturated fatty acid for nailcare
WO2011113000A8 (en) Novel ester containing compositions and methods
WO2011118957A3 (en) Composition for treating inflammatory, allergic or asthma diseases, containing paprika extracts
MX346316B (en) Pharmaceutical or neutraceutical formulation.
WO2009037705A3 (en) Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743443

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11743443

Country of ref document: EP

Kind code of ref document: A2